Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance

Journal of Infectious Diseases

Volumn 199, Issue 9, 2009, Pages 1323-1326

  Smith, Robert A ^a,b   Anderson, Donovan J ^a   Pyrak, Crystal L ^a   Preston, Bradley D ^a   Gottlieb, Geoffrey S ^b  

^a Departments of Pathology   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA, WESTERN; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; ZIDOVUDINE;

EID: 65649146417     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597802     Document Type: Article

References (15)

1. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999; 13(Suppl A):S69-84.
2. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
3. Menendez-Arias L, Tozser J. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci 2008; 29:42-9.
4. Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 2008; 52:329-32.
5. Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006; 20:1455-8.
6. Colson P, Henry M, Tivoli N, et al. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol 2005; 75:381-90.
7. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201.
8. Ruelle JP, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8:21.
9. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-35.
10. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2: e10.
11. Damond F, Collin G, Matheron S, et al. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir Ther 2005; 10:861-5.
12. van der Ende ME, Guillon C, Boers PH, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25: 11-8.
13. Smith RA, Anderson DJ, Preston BD. Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase. J Virol 2006; 80:7169-78.
14. HIV sequence compendium 2006/2007 (LA-UR number 07-4826). Leitner T, Foley B, Hahn B, et al., eds. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2007.
15. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-90.